JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models.

@article{Shibata1998JTT501AN,
  title={JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models.},
  author={Tatsuya Shibata and Kazuki Matsui and Fumihiko Yonemori and Korekiyo Wakitani},
  journal={British journal of pharmacology},
  year={1998},
  volume={125 8},
  pages={
          1744-50
        }
}
1. We investigated whether JTT-501 (4-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl]-3,5-isoxa zolidinedione) would improve insulin resistance in genetic (Zucker fatty rats) and non-genetic (high-fat fed rats) rodent models of obesity. 2. JTT-501 (10-100 mg kg(-1) day(-1)) was administered orally to Zucker fatty rats for 7-21 days. In the high-fat fed rat model, JTT-501 (100 mg kg(-1) day(-1) was administered orally for 7 days. In both models, JTT-501 improved metabolic abnormalities by… CONTINUE READING
BETA

Similar Papers

Loading similar papers…